SORINT - SORafenib for Treatment of Patients With INTermediate Stage Hepatocellular Carcinoma
Phase of Trial: Phase IV
Latest Information Update: 18 Nov 2015
Price : $35 *
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms SORINT
- Sponsors Bayer
- 18 Nov 2015 Status changed from active, no longer recruiting to completed.
- 06 Aug 2015 Planned End Date changed from 1 Jun 2015 to 1 Aug 2015 as per ClinicalTrials.gov record.
- 06 Aug 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Aug 2015 as per ClinicalTrials.gov record.